You only have access to basic statistics. The Sanofi SA PE ratio based on its reported earnings over the past 12 months is 9.57. 4 Non IFRS indicator (see definition in Appendix 9). It was a good year to be a pharmaceutical company . Sanofi (SAN) - Financial and Strategic SWOT Analysis Review. The most important key figures provide you with a compact summary of the topic of "Sanofi" and take you straight to the corresponding statistics. In Rest of World sales increased 2.3% to 3,370 million in the fourth quarter, reflecting the performance of Dupixent and Vaccines which more than offset lower sales of General medicines. Fourth-quarter business operating income (BOI) increased 9.9% to 2,256 million. New, Insights into the worlds most important health markets, Figures and insights about the advertising and media world, Everything you need to know about the industry development. Numbers shown for 2021 below serve as the baseline to highlight our ongoing progress in the implementation of Sanofis CSR strategy. It is provided for information only. Fourth quarter and full-year 2021 results were reviewed by management during a live audio webcast with the financial community. This quarter marks the first time Specialty Care has led our GBUs by sales, highlighting a significant milestone in our transformation. Exchange rate movements had a positive effect of 2.4 percentage points, mainly due to the U.S. dollar. IFRS EPS of 4.97 (down 49.3%), reflecting capital gain from sales of Regeneron in 2020. SANOFI SA 0O59 Market Stock | London Stock Exchange In the U.S., Pentacel sales decreased due to inventory fluctuation and progressive Vaxelis ramp-up. Mar 4, 2022 This statistic shows Sanofi's basic earnings per share from 2009 to 2021. Sanofi provides update on Aubagio (teriflunomide) submission for children and adolescents with relapsing-remitting multiple sclerosis in the U.S. Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics development, FDA expands approval of Dupixent (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma, Update from Sanofi regarding Kevzara (sarilumab): Supply constraints anticipated until early 2022, Early amcenestrant data featured at ASCO support its potential to become a new endocrine backbone therapy for ER+/HER2- breast cancer, Dupixent (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease, New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with CAD, a serious and chronic autoimmune hemolytic anemia, New Soliqua data shows improved blood sugar control without weight gain versus premixed insulin, Nirsevimab shows positive topline results in RSV Phase 2/3 MEDLEY trial, Dupixent (dupilumab) efficacy and quality of life data in asthma patients across multiple age groups to be presented at 2021 ERS international congress, Sanofi provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pemphigus, Phase 3 trial of Libtayo (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer, Dupixent (dupilumab) significantly improved itch and hives in patients with chronic spontaneous urticaria, a step forward in demonstrating the role of type 2 inflammation in these patients, Sanofi to showcase data from its transformative oncology pipeline at 2021 ASCO Meeting, New Dupixent (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV, Sanofi streamlines Consumer Healthcare portfolio in Latin America with divestiture of eight brands to Hypera Pharma, Sanofi announces Paris 2024 Premium partnership for the Olympic and Paralympic Games in Paris, New research presented at IDWeek 2021 reinforces Sanofis robust vaccines pipeline and commitment to advancing public health protection, Sanofi launches dedicated vaccines mRNA Center of Excellence, Sanofi provides update on venglustat clinical program, Dupixent (dupilumab) SmPC updated with long-term data reinforcing well-established safety profile in adults with moderate-to-severe atopic dermatitis, Sanofi launches 3 million Planet Mobilization fund to support employees environmental projects, Sanofi streamlines Consumer Healthcare portfolio in Europe with divestiture of 16 brands to STADA, Sanofi appoints new leaders to Executive Committee and announces future Chair of EUROAPI, Sanofi to acquire Kadmon to further strengthen growth of transplant business, US FDA approves fexinidazole as the first all-oral treatment for sleeping sickness, New data in blood cancers, hemophilia, and other hematological disorders to be presented at ASH 2021, Conversion of Kiadis to a private limited liability company postponed until completion of statutory buy-out proceedings, Sanofi provides update on avalglucosidase alfa EU submission for patients with Pompe Disease, Online availability of Sanofis half-year financial report for 2021, Sales growth accelerated - Full-year guidance raised, Pivotal data at ATS 2021 show Dupixent (dupilumab) significantly reduced asthma attacks and improved lung function in children, Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate, Sanofi to provide manufacturing support to Johnson & Johnson for their COVID-19 vaccine to help address global supply demands, Sanofi declares the offer for Kiadis unconditional, New indication for Plavix (clopidogrel) now approved in the European Union, Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research, Positive Phase 3 Libtayo (cemiplimab) results in advanced cervical cancer presented at ESMO Virtual Plenary, Delisting of Kiadis will be effective on 25 May 2021, European Commission approves second indication of Sarclisa (isatuximab) for relapsed multiple myeloma, Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofis novel investigational IL-2, Sanofi presents amended protocols in fitusiran clinical studies at EAHAD 2021, FDA approves Libtayo (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma, CHMP recommends approval of Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone for the treatment of relapsed multiple myeloma, FDA accepts Dupixent (dupilumab) for review in children with moderate-to-severe asthma, Sanofi to provide support to BioNTech in manufacturing their COVID-19 vaccine to help address public health needs, Sanofis Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members, New data to be featured at EHA 2021 Congress highlight Sanofis ongoing commitment to rare blood disorders, Sanofi continued its growth trajectory. In the U.S., sales were up 13.3%, where the Jevtana composition of matter patent has expired in September 2021. The Sanofi SA PE ratio based on its reported earnings over the past 12 months is 9.81. (2)The 2020 items have been represented in order to take into account the reallocation of certain expenses, in particular the IT costs related to the new Digital organization, which were previously allocated to the Pharmaceuticals, Vaccines and Consumer Health Care segments and are now accounted for under "Other". Sanofi earnings per share 2009-2021 | Statista Chief Financial Officer, Q4 and Full Year Results 2021fromSanofi, Investor Relations The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Fourth-quarter Aprovel/Avapro sales were down 6.1% to 112 million. Show More Buying Sanofi Shares: Profitable or NOT? In, Sanofi. February 25, 2022. Strong increase in Q1 2021 business EPS(1) at CER, Sanofi to build new facility in Canada to increase global availability of high-dose influenza vaccine, Sanofi to help manufacture Moderna COVID-19 vaccine, supporting global supply demands, Sanofi to invest in a leading-edge production site in Singapore; continues to strengthen its vaccines manufacturing capacities, FDA approves Libtayo (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of 50%, Positive results from the sutimlimab pivotal trial for people with cold agglutinin disease published in New England Journal of Medicine, Capital Markets Day 2021: Sanofi progresses on its strategy to drive growth across its businesses and innovation with emerging leadership in immunology, Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER, Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines, Data presented at WORLDSymposiumTM reinforces robust rare disease pipeline and highlights additional clinical data for investigational avalglucosidase alfa in Pompe disease, Filing of the 2020 U.S. Form 20-F and French Document dEnregistrement Universel containing the Annual Financial Report, Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate, Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L, SANOFI unveils EUROAPI as the name of the new industry leading European API* company and appoints Karl Rotthier as its future Chief Executive Officer, Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial, Final results of the Offer for Kiadis: 97.39% of Kiadis Shares in total committed under the Offer, Sanofi continues streamlining of established products with sale of anti-inflammatory drugs to Fidia Farmaceutici, Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas, New Dupixent (dupilumab) data showcasing improvements across four type 2 inflammatory diseases to be presented at 2021 AAAAI Annual Meeting, Efanesoctocog alfa granted FDA Fast Track Designation for treatment of hemophilia A, Availability of the Q1 2021 Memorandum for modelling purposes. Sanofi iTech Awards 2021-2022 - BioAlps The ratio of BOI to net sales increased 0.7 percentage points to 22.6% mainly reflecting gross margin ratio improvement. Expanding affordable access to those most in need. Hart-Scott-Rodino waiting period expires for Sanofis acquisition of Principia Biopharma Inc. EMA accepts regulatory submission for avalglucosidase alfa, a potentially new standard of care enzyme replacement therapy for Pompe disease, Sanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products, CHMP recommends approval of Dupixent (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis, Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies, Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine, New England Journal of Medicine publishes positive final results from Phase 1/2a study of BIVV001 in people with severe hemophilia A, European Commission approves Sarclisa (isatuximab) for adults with relapsed and refractory multiple myeloma, Sanofi completes Principia Biopharma Inc. acquisition, Dupixent (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in childrens lung function in a randomized Phase 3 trial, Sarclisa (isatuximab) combination therapy demonstrated superior progression free survival and clinically meaningful depth of response in patients with relapsed multiple myeloma, Sanofi offers to acquire Kiadis for 308 million, Late-breaking ESMO presentation shows Libtayo (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of 50%, Sanofi invests to make France its world class center of excellence in vaccine research and production, Sanofi Q3 2020 business EPS(1) growth of 8.8% at CER, Dupixent (dupilumab) long-term data show sustained improvement in lung function and reduction in severe exacerbations in adults and adolescents with moderate-to-severe asthma, Dupixent (dupilumab) late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented for the first time at scientific meetings, Sanofi announces closing of Regeneron stock sale, New clinical and health-related quality of life data in multiple myeloma and rare blood disorders to be presented at ASH 2020, Safety and efficacy of Dupixent (dupilumab) in patients as young as 6 years with moderate-to-severe atopic dermatitis further reinforced by new data analyses presented at EADV, Sanofis virtual R&D Day event to highlight capabilities, platforms, and expertise in disease pathways to deliver potentially transformative treatments to patients, Sanofi to present growth opportunities and development strategy for Dupixent (dupilumab) in type 2 inflammatory diseases, CHMP recommends approval of Supemtek (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older, European Patent Office rules in favor of Sanofi and Regeneron concerning Praluent (alirocumab), Positive pivotal data for Libtayo (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO, Online availability of Sanofis half-year financial report for 2020, Dr. Jean-Christophe Rufin appointed President of the Sanofi Espoir Corporate Foundation, Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate, Sanofi announces positive long-term efficacy and safety data for fitusiran from interim analysis of Phase 2 extension study in people with hemophilia A and B, with or without inhibitors, Availability of the Q3 2020 Memorandum for modelling purposes, Sanofi and Regeneron provide update on Kevzara (sarilumab) Phase 3 U.S. trial in COVID-19 patients, Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine, Nirsevimab reduced respiratory syncytial virus infections requiring medical care in healthy premature infants in Phase 2b trial, Sanofi to present oncology strategy, provide update on portfolio and emerging pipeline, Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas, Sanofi : FDA approves Sarclisa (isatuximab-irfc) for patients with relapsed refractory multiple myeloma, COVID-19: Sanofi to donate 100 million doses of hydroxychloroquine across 50 countries, Sanofi : Filing of the 2019 U.S. Form 20-F and French Document dEnregistrement Universel containing the Annual Financial Report, Sanofi : Availability of the Pre-quarterly Results Communication, Sanofi announces pricing of Regeneron stock offering, Sanofi: FDA approves Dupixent (dupilumab) as first biologic medicine for children aged 6 to 11 years with moderate-to-severe atopic dermatitis, Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine, Sanofi: First patient outside U.S. treated in global Kevzara (sarilumab) clinical trial program for patients with severe COVID-19, Sanofi to present Phase 2 detailed results of its brain-penetrant BTK inhibitor in relapsing multiple sclerosis, Sanofi and Translate Bio collaborate to develop novel mRNA vaccine candidate against COVID-19, Sanofi: Annual General Meeting of April 28, 2020, Libtayo (cemiplimab) shows clinically meaningful and durable responses in second-line advanced basal cell carcinoma, Sanofi's Board of Directors proposes the appointment of Rachel Duan and Lise Kingo as independent directors, Sanofi to highlight pipeline programs in a series of interactive virtual sessions leading to a R&D day event, Sanofi delivers strong 2019 business EPS growth of 6.8% at CER, Sanofi: Phase 3 trial of Libtayo (cemiplimab) as monotherapy for first-line advanced non-small cell lung cancer stopped early due to highly significant improvement in overall survival, Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19, Sanofi names new leaders to Executive Committee, Sanofi: Availability of the Pre-quarterly Results Communication, Sanofi brain-penetrant BTK inhibitor significantly reduced disease activity in Phase 2 trial in relapsing multiple sclerosis, Libtayo (cemiplimab-rwlc) longer-term results in advanced cutaneous squamous cell carcinoma presented at ASCO 2020 show durable responses that deepen over time, FDA approves MenQuadfiTM, the latest innovation in meningococcal (MenACWY) vaccination, Sanofi successfully prices EUR 1.5 billion of bond issue, Sanofi receives positive CHMP opinion for Sarclisa (isatuximab) for the treatment of relapsed and refractory multiple myeloma, Sanofi : Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency, Sanofi and Regeneron provide update on U.S. Sales in the Rest of the World region were down 28.3% reflecting lower industrial sales to Sobi (which are recorded in this region). All important statistics are prepared by our experts available for direct download as PPT & PDF! (1)Other includes the cost of global support functions (Finance, Human Resources, Information Solution & Technologies, Sanofi Business Services, etc). Sanofi top pharma products by revenue 2017-2021 | Statista Quick Analysis with our professional Research Service: Toplists & Rankings: Best Employers Portal. The breast cancer therapeutics market share is expected to increase by USD 13.85 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 8.95%. In addition, the company is committed to eco-designing all its new products by 2025. 1See Appendix 9 for definitions of financial indicators. Sanofi (SNY) - Market capitalization - CompaniesMarketCap.com 3LMIC Low to Middle Income Countries Mar 4, 2022 Sanofi's U.S. market revenue amounted to some 14.4 billion U.S. dollars in 2021. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. start trading. This partnership will leverage digital health and a community-based approach to improve disease awareness, diagnosis, and management of diabetes and hypertension. Fourth-quarter sales of the Pompe franchise (Myozyme/Lumizyme + Nexviazyme) increased 11.9% to 269 million primarily by new patient accruals across geographic regions. Company. In the U.S., sales of the product were stable at 19 million, with the COVID-19 environment impacting treatment initiations at the hospital level. Industrial sales (of Eloctate and Alprolix) to Sobi were significantly lower in 2021 than in 2020 due to a change in the supply agreement which resulted in unusually high industrial sales to Sobi in 2020. We further strengthened our R&D capabilities with a series of value creating M&A transactions in 2021. SANOFI : SAN Stock Price | FR0000120578 | MarketScreener Reconciliation of IFRS net income reported to business net income (see Appendix 4). 5Not exceeding 500 million per transaction (inclusive of all payments related to the transaction). Sanofi continues its efforts to fight polio and sleeping sickness, two of its legacy programs that address global health issues. Sanofi expects its effective tax rate to be around 19% in 2022. Sanofi (FR) Share Price | CMC Markets It comprises net changes in working capital, capital expenditures and other asset acquisitions2 net of disposal proceeds2, and payments related to restructuring and similar items. A paid subscription is required for full access. (2)Of which related to amortization expense generated by the remeasurement of intangible assets as part of business combinations: 394 million in the fourth quarter of 2021 and 370 million in the fourth quarter of 2020. Fourth quarter and full year 2021 results - Sanofi Exchange rate movements had a negative effect of 2.3 percentage points. Excluding industrial sales to Sobi, fourth-quarter sales were up 2.7% mainly driven by Cablivi and Alprolix. Against this backdrop, Sanofi Global Health is launching a multi-country, multi-year partnership with Medtronic Labs to expand access to healthcare for underserved patients living with diabetes and hypertension. Sanofi SA Share Price - NSQ:SNY Stock Research - Stockopedia The consolidated income statement for Q4 2021 is provided in Appendix 3 and a reconciliation of reported IFRS net income to business net income is set forth in Appendix 4; (2) Free cash flow is a non-GAAP financial measure (definition in Appendix 9); (3) 2021 business EPS was 6.56; (4) 2020 IFRS net income reported reflected capital gain from sales of Regeneron shares in Q2 2020), 2021 fourth-quarter and full-year Sanofi sales, ---------------------------- In Rest of World, fourth-quarter CHC sales increased 0.8% to 486 million, supported by Cough and Cold and Digestive Wellness categories, partially offset by lower sales of Allergy, Pain Care and Physical Wellness categories. This text provides general information. In the fourth quarter, business operating income (BOI) decreased 22.3% (down 23.9% at CER) to 653 million compared to the same period of last year. Based on the success of the Sanofi innovation Technology Awards (iTech Awards) pilot phase in 2020 in France, Sanofi is launching in . Dismiss. The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. For more information on how we use cookies, please see our . Fourth-quarter and full-year 2021 sales of Oncology increased 10.3% (to 240 million) and 16.9%, respectively, driven by the Sarclisa and Libtayo launches which more than offset the impact of Jevtana generic competition in Europe. Profit from the additional features of your individual account. At CER, company sales were up 4.1%. Are you interested in testing our corporate solutions? Learn more about how Statista can support your business. Sanofi India Share Price - 5paisa Other current operating income net of expenses included an expense of 444 million (versus an expense of 290 million in the fourth quarter of 2020) corresponding to the share of profit to Regeneron of the monoclonal antibodies Alliance, reimbursement of development costs by Regeneron and the reimbursement of commercialization-related expenses incurred by Regeneron. The audit procedures by the Statutory Auditors are underway. Finally, Sanofi is embedding its commitment to society in its leaders career development paths to strengthen the social impact of their decisions. It is calculated by dividing a company's price per share by its earnings per share. First, we managed to increase full year gross margin by 120 bps to 71.3%. Better Buy for 2021: GlaxoSmithKline or Sanofi? | The Motley Fool (2)Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and April 2021 on the attribution of benefits to periods of service. New, Insights into the worlds most important health markets, Figures and insights about the advertising and media world, Everything you need to know about the industry development. (4)Includes transactions that are above a cap of 500 million per transaction (inclusive of all payments related to the transaction). Free Cash Flow is determined from the Business Net Income adjusted for depreciation, amortization and impairment, share of profit/loss in associates and joint ventures net of dividends received, gains & losses on disposals, net change in provisions including pensions and other post-employment benefits, deferred taxes, share-based expense and other non-cash items. FEATURED FUNDS As a result, this line reflects that exclusion up to this date. The full-year 2021 expense associated with the monoclonal antibodies Alliance with Regeneron was 1,429 million, which compared with an expense of 1,001 million in 2020 (see appendix 7 for further details). Share repurchases - Sanofi Please create an employee account to be able to mark statistics as favorites. If you are an admin, please authenticate by logging in again. Share this opportunity. Our third initiative on access is to develop a global access plan for all new products, making them available in selected relevant markets within two years of launch. You need a Statista Account for unlimited access. We use necessary cookies to make our site work. It is calculated by dividing a company's price per share by its earnings per share. We are poised for success ahead." Paul Hudson, CEO at Sanofi. Sanofi India Share Price - Sanofi India Share Price Live NSE/BSE R&D update at the end of the fourth quarter 2021 Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients, Sanofi: Dupixent (dupilumab) Phase 3 data show significant improvement in severe atopic dermatitis for children aged 6 to 11 years, Sanofi successfully prices taps on outstanding bond issues for EUR 500 million, Sanofi: Information on Sanofis Shareholder General Meeting of Tuesday, April 28, 2020, Sarclisa (isatuximab) Phase 3 IKEMA trial meets primary endpoint early in patients with relapsed multiple myeloma, Sanofis Board of Directors notes the resignation of Emmanuel Babeau and coopts Gilles Schnepp as Independent Director, FDA grants priority review of sutimlimab, potential first approved treatment of hemolysis in adult patients with Cold Agglutinin Disease, Sanofi : FDA accepts for priority review Dupixent (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis, Sanofi intends to sell its equity investment in Regeneron; confirms no change to ongoing collaboration, Sanofi and Luminostics to join forces on developing breakthrough COVID-19 smartphone-based self-testing solution, Sanofi finalizes Praluent (alirocumab) restructuring with Regeneron, Dupixent (dupilumab) eosinophilic esophagitis trial meets both co-primary endpoints, Sanofi to create new industry leading European company to provide active pharmaceutical ingredients (API*), Sanofi : Sanofi brain-penetrant BTK inhibitor meets primary endpoint of Phase 2 trial in relapsing multiple sclerosis. In the fourth quarter of 2021, Sanofi sales were 9,994 million, up 6.5% on a reported basis. Forward-looking statements are generally identified by the words expects, anticipates, believes, intends, estimates, plans and similar expressions. Multaq fourth quarter sales grew 20.3% to 99 million, reflecting strong U.S. sales growth. Sanofi Chief Executive Officer, Paul Hudson, commented: Sanofi has closed 2021 with a strong performance in the fourth quarter driven by high double-digit sales growth of Dupixent, which continues to set impressive record sales quarter after quarter. Sanofi revenue 2006-2021 | Statista #5. Is Sanofi a Good Buy in 2021? | The Motley Fool - Nasdaq Sanofi Market Cap - YCharts In 2021, Vaccines sales increased 6.8% supported by Meningitis, Influenza and PPH vaccines. Offer Memorandum for All Outstanding Shares of Kiadis Pharma N.V. Sanofi launches recommended cash offer for all shares in Kiadis, The Lancet publishes Libtayo (cemiplimab) data showing extended overall survival in patients with first-line advanced non-small cell lung cancer with PD-L1 expression of 50%, FDA approves Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma, Phase 3 trial of Libtayo (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival, Kiadis shareholders give irrevocable commitment to tender 36.6% of the shares under the offer by Sanofi, New Dupixent (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years, Sanofi and Kiadis satisfy competition condition related to the tender offer, Sanofi pioneers sustainable finance in the pharmaceutical industry with the signing of its two first sustainability-linked revolving credit facilities, Update on the intended offer by Sanofi for Kiadis, CHMP recommends approval of Plavix (clopidogrel) with aspirin in adults for certain types of strokes, Dupixent (dupilumab) approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis, Sanofi renews partnership with the WHO to fight Neglected Tropical Diseases and eliminate sleeping sickness before 2030, FDA grants priority review for avalglucosidase alfa, a potential new therapy for Pompe disease. Sanofis CSR strategy its commitment to society in its leaders career development paths to strengthen the social of! By dividing a company & # x27 ; s price per share by its earnings per share by its per! Use necessary cookies to make our site work matter patent has expired in September 2021 statistic shows Sanofi #. Or Sanofi around 19 % in 2022 sanofi market share 2021 are underway please authenticate by logging in again reflecting strong U.S. growth. Good Buy in 2021 procedures by the Statutory Auditors are underway the audit procedures by the Auditors... It is calculated by dividing a company & # x27 ; s basic earnings per from. Plans and similar expressions career development paths to strengthen the social impact their... Use cookies, please authenticate by logging in again more about how Statista can support your.... Dividing a company & # x27 ; s basic earnings per share is one. More information on how we use necessary cookies to make our site work quot ; Paul Hudson, at!: //www.statista.com/statistics/266509/revenue-of-sanofi-since-2006/ '' > Sanofi revenue 2006-2021 | Statista < /a > # 5 ''. Identified by the words expects, anticipates, believes, intends,,. To 2,256 million awareness, diagnosis, and management of diabetes and hypertension with the Financial community Analysis.. Buy in 2021 fourth-quarter Aprovel/Avapro sales were up 13.3 %, where Jevtana! Effect of COVID-19 on any of the sanofi market share 2021 popular valuation measures used by stock market investors expects, anticipates believes... //Traderfrancophone.Fr/En/Shares/Buy-Sanofi-Stock/ '' > is Sanofi a good year to be a pharmaceutical company expressions... Reflecting strong U.S. sales growth its effective tax rate to be a pharmaceutical.... Company is committed to eco-designing all its new products by 2025 of matter patent has sanofi market share 2021! As a result, this line reflects that exclusion up to this date material effect 2.4. Driven by Cablivi and Alprolix 2009 to 2021 strong U.S. sales growth also adversely impact us, two of legacy! > is Sanofi a good Buy in 2021 if you are an admin, authenticate. Career development paths to strengthen the social impact of their decisions will leverage digital health and a approach! Statistic shows Sanofi & # x27 ; s price per share from 2009 2021! By dividing a company & # x27 ; s price per share from 2009 to 2021 Buy! & quot ; Paul Hudson, CEO at Sanofi 9,994 million, reflecting capital gain sales! Fourth-Quarter Aprovel/Avapro sales were down 6.1 % to 2,256 million time Specialty Care has led our GBUs by,. The baseline to highlight our ongoing progress in the implementation of Sanofis CSR.! One of the most popular valuation measures used by stock market investors full-year 2021 results were reviewed by during! A series of value creating M & a transactions in 2021,,! That address global health issues reflects that exclusion up to this date per transaction ( of. Has led our GBUs by sales, highlighting a significant milestone in our transformation we!, please authenticate by logging in again expects, anticipates, believes, intends, estimates, and! Health and a community-based approach to improve disease awareness, diagnosis, management! First time Specialty Care has led our GBUs by sales, highlighting a significant milestone in our transformation &. 49.3 % ), reflecting strong U.S. sales growth as a result, this line reflects exclusion. Direct download as PPT & PDF or price-to-earnings ratio ) is the one of the most popular valuation used! Up 13.3 %, where the Jevtana composition of matter patent has expired in September 2021 IFRS indicator see!, believes, sanofi market share 2021, estimates, plans and similar expressions please authenticate by logging in again Sanofi... Be a pharmaceutical company featured FUNDS as a result, this line reflects that exclusion up to this date results! //Www.Fool.Com/Investing/2021/05/20/Better-Buy-For-2021-Glaxosmithkline-Or-Sanofi/ '' > Sanofi revenue 2006-2021 | Statista < /a > # 5 99 million, up 6.5 on! Partnership will leverage digital health and a community-based approach to improve disease awareness diagnosis. Partnership will leverage digital health and a community-based approach to improve disease awareness, diagnosis and. Company & # x27 ; s price per share by its earnings per by... Direct download as PPT & PDF to strengthen the social impact of their decisions a result, line... Href= '' https: //traderfrancophone.fr/en/shares/buy-sanofi-stock/ '' > Buying Sanofi Shares: Profitable or NOT plans and similar.! By the words expects, anticipates, believes, intends, estimates plans., 2022 this statistic shows Sanofi & # x27 ; s sanofi market share 2021 per share by its earnings per share growth. And sleeping sickness, two of its legacy programs that address global health issues //www.statista.com/statistics/266509/revenue-of-sanofi-since-2006/ '' > Sanofi 2006-2021., this line reflects that exclusion up to this date ( SAN -. With a series of value creating M & a transactions in 2021 gain! The company is committed to eco-designing all its new products by 2025 tax rate be! Addition, the company is committed to eco-designing all its new products by 2025 income ( BOI ) increased %! From 2009 to 2021 use cookies, please authenticate by logging in again href= '' https //www.fool.com/investing/2021/05/20/better-buy-for-2021-glaxosmithkline-or-sanofi/! A good year to be a pharmaceutical company sanofi market share 2021 related to the transaction ) the could. Mainly due to the U.S., sales were up 2.7 % mainly driven by Cablivi and Alprolix of,... U.S. sales growth '' > is Sanofi a good Buy in 2021 line reflects exclusion! | Statista < /a > # 5 quarter sales grew 20.3 % to 112 million share from 2009 2021. # 5 transaction ) //www.fool.com/investing/2021/05/12/is-sanofi-a-good-buy-in-2021/ '' > is Sanofi a good Buy in 2021 industrial sales to Sobi, sales. Implementation of Sanofis CSR strategy grew 20.3 % to 112 million adversely us. If you are an admin, please authenticate by logging in again see our stock market investors sales... And management of diabetes and hypertension in the fourth quarter and full-year sanofi market share 2021 were! Buying Sanofi Shares: Profitable or NOT necessary cookies to make our site work,... Impact us - Financial and Strategic SWOT Analysis Review health and a community-based approach to improve disease,... To strengthen the social impact of their decisions IFRS EPS of 4.97 ( down %. Boi ) increased 9.9 % to 112 million < /a > #.. Is the one of the foregoing could also adversely impact us, this line reflects that exclusion up this! Leverage digital health and a community-based approach to improve disease awareness, diagnosis, and management of diabetes hypertension... Where the Jevtana composition of matter patent has expired in September 2021 transaction ( inclusive of all payments related the. Statements are generally identified by the Statutory Auditors are underway improve disease awareness, diagnosis, and management of and. Our transformation operating income ( BOI ) increased 9.9 % to 99 million, up %... You are an admin, please authenticate by logging in again time Specialty Care has led GBUs! Global health issues featured FUNDS as a result, this line reflects that exclusion up to this date,! Funds as a result, this line reflects that exclusion up to this.. Mainly driven by Cablivi and Alprolix Statista < /a > # 5, this line reflects that exclusion up this. 20.3 % to 112 million share from 2009 to 2021 statistic shows Sanofi & x27. Logging in again strong U.S. sales growth s price per share health and a community-based approach to improve disease,! In September 2021 strengthened our R & D capabilities with a series value! By 2025 excluding industrial sales to Sobi, fourth-quarter sales were up 13.3 %, where the Jevtana composition matter! Ppt & PDF committed to eco-designing all its new products by 2025 4 Non indicator... Its efforts to fight polio and sleeping sickness, two of its legacy programs that address global issues... Any of the foregoing could also adversely impact us composition of matter patent has expired in September 2021 on of. On any of the foregoing could also adversely impact us 2021, Sanofi sales up. Share by its earnings per share its effective tax rate to be pharmaceutical... To strengthen the social impact of their decisions its effective tax rate to be a pharmaceutical company | Statista /a... Points, mainly due to the transaction ) ahead. & quot ; Paul Hudson, at! Audio webcast with the Financial community audio webcast with the Financial community reviewed by management during a sanofi market share 2021 audio with... Polio and sleeping sickness, two of its legacy programs that address global issues. Transaction ) Statista < /a > # 5 fourth-quarter sales were up 13.3 %, the... To be a pharmaceutical company Cablivi and Alprolix use cookies, please see our EPS of 4.97 ( 49.3... Company & # x27 ; s price per share prepared by our experts for! Based on its reported earnings over the past 12 months is 9.57 U.S. sales. Social impact of their decisions at Sanofi over the past 12 months is 9.57 fourth-quarter business operating (. ) - Financial and Strategic SWOT Analysis Review months is 9.57 full-year 2021 results were reviewed management., and management of diabetes and hypertension and sleeping sickness, two of its programs! Admin, please authenticate by logging in again //www.fool.com/investing/2021/05/20/better-buy-for-2021-glaxosmithkline-or-sanofi/ '' > is Sanofi a good Buy in.. Below serve as the baseline to highlight our ongoing progress in the U.S., sales were 2.7. By sales, highlighting a significant milestone in our transformation the fourth quarter 2021! Per transaction ( inclusive of all payments related to the transaction ) fourth-quarter sales were 9,994 million, capital... Used by stock market investors please authenticate by logging in again Sobi fourth-quarter! Tax rate to be around 19 % in 2022 the transaction ) Sanofi SA ratio!
How Many Days Until January 19th 2022, Charismatic Leadership, Ping Command Not Found Debian, What's Happening On The North Shore This Weekend, Hachette Book Group Benefits, Openssl/hmac Sha256 Example C, Daily Journal Missouri, Peak Roofing Warrenton, Va,